Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Cantor Fitzgerald Reiterates Overweight Rating on Soleno Therapeutics Inc. (SLNO)
-
Cantor Fitzgerald Reiterates Overweight Rating on Palo Alto Networks (PANW)
-
Cantor Fitzgerald Reiterates Overweight Rating on PureCycle Technolgies (PCT)
-
Form 424B3 Cantor Fitzgerald Income
-
Terawulf Inc. (WULF) PT Raised to $14 at Cantor Fitzgerald
-
Denison Mines closes US$345 million convertible notes offering
-
Denison Announces Closing of US$345 Million Convertible Senior Notes Offering
-
Applied Materials (AMAT) PT Lowered to $200 at Cantor Fitzgerald following disappointing Q3 results
-
Evolv Technologies Holdings Inc. (EVLV) PT Raised to $9 at Cantor Fitzgerald amid pivot to subscription model
-
Cantor Fitzgerald Reiterates Overweight Rating on SanDisk (SNDK)
-
Cantor Fitzgerald reiterates Overweight rating on CyberArk Software (CYBR), eyes $25B Palo Alto deal
-
Cantor Fitzgerald reiterates Neutral rating on Fortinet (FTNT), refresh cycle 40–50% complete
-
Cantor Fitzgerald Reiterates Neutral Rating on Checkpoint Software (CHKP)
-
Cantor Fitzgerald Reiterates Overweight Rating on Varonis Systems (VRNS)
-
Cantor Fitzgerald reiterates Overweight rating on JFrog (FROG) following 'impressive beat'
-
Cantor Fitzgerald Reiterates Overweight Rating on Tenable (TENB)
-
Cantor Fitzgerald Starts Exodus Movement, Inc. (EXOD) at Overweight
-
Cantor Fitzgerald Starts Avalo Therapeutics Inc. (AVTX) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on Palo Alto Networks (PANW)
-
Form SCHEDULE 13G OnKure Therapeutics, Filed by: CANTOR FITZGERALD & CO.
-
Kyivstar Group completes SPAC merger, set to trade on NASDAQ as KYIV
-
Kyivstar Group completes merger with Cohen Circle ahead of NASDAQ listing
-
Ahead of Its Historic Listing on Nasdaq, Kyivstar Group Completes Business Combination with Cohen Circle
-
Ahead of Its Historic Listing on Nasdaq, Kyivstar Group Completes Business Combination with Cohen Circle
-
Ahead of Its Historic Listing on Nasdaq, Kyivstar Group Completes Business Combination with Cohen Circle
-
Form 13F-NT CANTOR FITZGERALD & CO. For: Jun 30
-
Form 13F-HR CANTOR FITZGERALD, L. For: Jun 30
-
Form 13F-NT Cantor Fitzgerald Europe For: Jun 30
-
Kimball Electronics (KE) PT Raised to $27 at Cantor Fitzgerald
-
Merlin to go public via SPAC merger valued at $800 million
-
Merlin to Go Public via Business Combination with Inflection Point-led SPAC as Leading Defense Prime Contractor for AI in Aviation
-
Cantor Fitzgerald Reiterates Overweight Rating on Alumis Inc (ALMS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Codexis, Inc. (CDXS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Aardvark Therapeutics Inc (AARD)
-
Cantor Fitzgerald Reiterates Overweight Rating on United Therapeutics Corp. (UTHR)
-
Eve raises $230 million through equity offering and Brazil listing
-
Eve Announces $230 Million Equity Capital Raise and Dual Listing in the United States and Brazil
-
Cantor Fitzgerald Starts Workday (WDAY) at Overweight
-
Cantor Fitzgerald Starts Paycom Software (PAYC) at Neutral
-
Cantor Fitzgerald Starts Paylocity Holding (PCTY) at Overweight
-
Robinhood Markets (HOOD) PT Raised to $128 at Cantor Fitzgerald, 'a must-own name', 'Record Month for HOOD'
-
EnviroGold Global Retains Cantor Fitzgerald as Financial Advisor
-
Aquestive Therapeutics prices $85 million stock offering
-
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
-
Form 10-Q Cantor Fitzgerald Income For: Jun 30
-
Aquestive secures $75 million funding from RTW for Anaphylm launch
-
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
-
Orchid Island Capital Announces August 2025 Monthly Dividend and July 31, 2025 RMBS Portfolio Characteristics
-
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
AleraCare and PURE Healthcare Announce Intent to Merge
